# US 2013/0157936 A1 · Modulation of ghrelin levels and ghrelin/unacylated ghrelin ratio using unacylated ghrelin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0157936 A1
- Document ID: US20130157936A1
- Status: Published application
- Kind: A1
- Application number: 13/715,550
- Filed: 2012-12-14
- Published: 2013-06-20
- Earliest claimed: 2011-12-15
- Assignees: Alize Pharma SAS
- Inventors: Aart Jan VAN DER LELY; Thierry ABRIBAT
- Web page: https://patentgrep.com/patent/US20130157936A1

## CPC

- C07K 14/575: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695)
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 38/2264: {Obesity-gene products, e.g. leptin}
- A61K 38/25: Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07K 5/10: Tetrapeptides
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- G01N 33/74: involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors}
- G01N 2333/62: Insulins
- G01N 2800/042: Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
- G01N 2800/044: Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A method and a composition for decreasing ghrelin levels and/or decreasing ghrelin/unacylated ghrelin ratio in a subject, the method comprising administering an effective amount of unacylated ghrelin, a fragment thereof, an analog thereof and/or pharmaceutically acceptable salts thereof to the subject wherein a reduction in ghrelin levels and/or a reduction in ghrelin/unacylated ghrelin ratio is beneficial to the subject. Also, use of ghrelin level and/or ghrelin/unacylated ghrelin ratio as biomarkers for determining a subject's likelihood of responding to and/or benefiting from administration of unacylated ghrelin.

## Claims

### Claim 1

A method for decreasing ghrelin levels in a subject, comprising administering an effective amount of unacylated ghrelin, a fragment thereof, an analog thereof and/or pharmaceutically acceptable salts thereof to the subject.

### Claim 2 (depends on 1)

The method as defined in claim 1, wherein the ghrelin levels are elevated circulating ghrelin levels.

### Claim 3 (depends on 1)

The method as defined in claim 1, wherein the ghrelin levels are associated with at least one of hyperglycemia, insulin resistance, reduced fat utilization, adiposity, weight gain and suppression of insulin secretion in the subject.

### Claim 4 (depends on 1)

The method as defined in claim 1, wherein the subject suffers from a condition selected from the group consisting of type 2 diabetes, hyperghrelinemia, obesity associated with insulin resistance and Prader-Willi Syndrome and any combination thereof.

### Claim 5 (depends on 1)

The method as defined in claim 1, for decreasing a ghrelin/unacylated ghrelin ratio in a subject.

### Claim 6 (depends on 5)

The method as defined in claim 5, wherein the ghrelin/unacylated ghrelin ratio is an elevated circulating ghrelin/unacylated ghrelin ratio.

### Claim 7 (depends on 1)

The method as defined in claim 1, wherein the unacylated ghrelin has an amino acid sequence as set forth in SEQ ID NO: 1.

### Claim 8 (depends on 1)

The method as defined in claim 1, wherein the unacylated ghrelin fragment comprises an amino acid sequence as set forth in SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12 or SEQ ID NO: 25.

### Claim 9 (depends on 1)

The method as defined in claim 1, wherein the unacylated ghrelin fragment has an amino acid sequence as set forth in SEQ ID NO: 6.

### Claim 10 (depends on 1)

The method as defined in claim 1, wherein the unacylated ghrelin fragment has an amino acid sequence as set forth in SEQ ID NO: 25.

### Claim 11 (depends on 1)

The method as defined in claim 1, wherein the effective amount is from about 0.001 μg/kg to about 10 μg/kg.

### Claim 12 (depends on 1)

The method as defined in claim 1, wherein effective amount is from about 1 μg/kg to about 1 mg/kg.

### Claim 13

A method for preventing weight gain in a subject following diet-induced weight loss, comprising administering an effective amount of unacylated ghrelin, a fragment thereof, an analog thereof and/or pharmaceutically acceptable salts thereof to the subject.

### Claim 14 (depends on 13)

The method as defined in claim 13, wherein the administration of the unacylated ghrelin, the fragment thereof, the analog thereof and/or the pharmaceutically acceptable salts thereof decreases ghrelin levels.

### Claim 15

A pharmaceutical composition comprising an effective amount of unacylated ghrelin, a fragment thereof, an analog thereof and/or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable diluent for decreasing ghrelin levels in a subject.

### Claim 16 (depends on 15)

The pharmaceutical composition as defined in claim 15, wherein the unacylated ghrelin fragment has an amino acid sequence as set forth in SEQ ID NO: 25.

### Claim 17

A method for screening within a population of subjects suffering from diabetes, Prader-Willi Syndrome, obesity, insulin resistance or hyperphagia, which subjects within the population are susceptible of benefiting from an administration of unacylated ghrelin, a fragment thereof or an analog thereof, comprising:
determining a level of circulating ghrelin from the subjects of the population;
processing the level of circulating ghrelin at least in part based on a reference level of circulating ghrelin to derive information conveying whether the level of circulating ghrelin is elevated; and
causing conveyance of the information to a recipient for determining the subject's susceptibility of benefiting from administration of unacylated ghrelin, a fragment thereof or an analog thereof.

### Claim 18 (depends on 17)

The method as defined in claim 17, further comprising administering a therapeutically effective amount of unacylated ghrelin, a fragment thereof, an analog thereof and/or pharmaceutically acceptable salts thereof to the subjects that are susceptible of benefiting from administration of unacylated ghrelin, a fragment thereof or an analog thereof.

### Claim 19 (depends on 17)

The method as defined in claim 17, wherein the level of circulating ghrelin is elevated when it is above the normal level of circulating ghrelin.

### Claim 20 (depends on 17)

The method as defined in claim 17, further determining a ratio of circulating ghrelin/unacylated ghrelin from the subjects of the population;
processing the ratio of circulating ghrelin/unacylated ghrelin at least in part based on a reference ratio of circulating ghrelin/unacylated ghrelin to derive information conveying whether the ratio of circulating ghrelin/unacylated ghrelin is elevated; and
causing conveyance of the information to a recipient for determining the subject's susceptibility of benefiting from administration of unacylated ghrelin.

### Claim 21 (depends on 20)

The method as defined in claim 20, wherein the ratio of circulating ghrelin/unacylated ghrelin is elevated when it is above the normal ratio of circulating ghrelin/unacylated ghrelin.

### Claim 22 (depends on 18)

The method as defined in claim 18, wherein the subjects of the population suffer from Type 2 diabetes.
